ETF1

Across TCGA pan-cancer cohorts, ETF1 Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated ETF1 data layer compared with 25 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher ETF1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ETF1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUSC, LUAD, and LIHC are the cancer types where ETF1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	II,III,IV	0.112	0.743	<.001	26	view →
LUAD	OS	Median	All	0.228	0.812	.001	24	view →
LIHC	OS	Median	All	0.125	0.707	<.001	24	view →
CESC	DFS	Median	All	0.204	0.745	<.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LGG	DFS	Median	All	0.077	0.845	<.001	6	view →
ESCA	OS	Median	II,III,IV	0.321	0.685	.035	6	view →
COAD	DFS	Median	All	0.193	0.697	.002	6	view →
SKCM	DFS	Median	III,IV	0.099	0.655	.001	6	view →
UCEC	DFS	Median	II,III,IV	0.868	0.305	.031	2	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

ETF1–LUSC (OS)

Open the LUSC breakdown →